Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07226453 · ClinicalTrials.gov registry record · Phase 2
Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma
A Phase 2 study of Posterior Fossa Ependymal Tumor, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT07226453: Recruiting Phase 2 study of Posterior Fossa Ependymal Tumor, sponsored by University of California, San Francisco.
NCT07226453 is a Phase 2 study of Posterior Fossa Ependymal Tumor that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 30 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07226453, a Phase 2 study of Posterior Fossa Ependymal Tumor, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a multi-site study of the pharmacodynamic effects and efficacy of metformin in children and young adults with recurrent or progressive Posterior Fossa Group A (PFA) ependymoma.
Primary Outcome
Proportion of participants with a 10% reduction in Enhancer of Zeste Inhibitory Protein (EZHIP) and/or a 10% increase in the epigenetic modification to the DNA packaging protein histone H3, with tri-methylation of lysine 27 on histone H3 (H3K27me3) between the pre- and post-metformin treated samples by Immunohistochemistry (IHC).
Conditions Studied
Interventions
- DRUG Metformin
- PROCEDURE Magnetic Resonance Imaging (MRI)
- PROCEDURE Specimen Collection
- PROCEDURE Planned Surgical Resection
- PROCEDURE MR spectroscopy (MRS)
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-03-04 |
| Est. Completion | 2030-03-31 |
| Phase | Phase 2 |
What NCT07226453 shows while recruiting
NCT07226453 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Posterior Fossa Ependymal Tumor appearing as the primary indexed condition, and to 5 interventions - of which Metformin is the first listed.
NCT07226453 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07226453 about?
NCT07226453 is a clinical study titled "Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma". This is a multi-site study of the pharmacodynamic effects and efficacy of metformin in children and young adults with recurrent or progressive Posterior Fossa Group A (PFA) ependymoma.
What is the current status of trial NCT07226453?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2026-03-04. Estimated completion is 2030-03-31.
What conditions does trial NCT07226453 study?
This clinical trial studies the following conditions: Posterior Fossa Ependymal Tumor.
What interventions are being tested in trial NCT07226453?
The interventions under investigation include: Metformin (DRUG), Magnetic Resonance Imaging (MRI) (PROCEDURE), Specimen Collection (PROCEDURE), Planned Surgical Resection (PROCEDURE), MR spectroscopy (MRS) (PROCEDURE).
Who is sponsoring clinical trial NCT07226453?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07226453 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07226453's enrollment target sits among peer trials
30 1582nd of 2000 higher than 332 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI